Identification of myocardial injury in the emergency setting

Clinical Biochemistry

Volumn 43, Issue 6, 2010, Pages 539-544

  Kavsak, Peter A ^a   Worster, Andrew ^a   You, John J ^a,b   Oremus, Mark ^a   Elsharif, Adell ^a   Hill, Stephen A ^a   Devereaux, P J ^a   MacRae, Andrew R ^c   Jaffe, Allan S ^d  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF MANITOBA   (Canada)

^d MAYO CLINIC   (United States)

Author keywords

AMI; Biomarker panels; Emergency department; Hs cTn

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CREATINE KINASE MB; FATTY ACID BINDING PROTEIN; GROWTH DIFFERENTIATION FACTOR 15; INTERLEUKIN 6; MYELOPEROXIDASE; MYOGLOBIN; PREGNANCY ASSOCIATED PLASMA PROTEIN A; TROPONIN C;

ACUTE HEART INFARCTION; CARDIOVASCULAR RISK; EARLY DIAGNOSIS; EMERGENCY CARE; EMERGENCY WARD; HEART MUSCLE INJURY; HUMAN; PATIENT IDENTIFICATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW;

DIAGNOSTIC TECHNIQUES, CARDIOVASCULAR; EARLY DIAGNOSIS; EMERGENCY SERVICE, HOSPITAL; HEART INJURIES; HUMANS; MYOCARDIAL INFARCTION; MYOCARDIUM; POINT-OF-CARE SYSTEMS; PRACTICE GUIDELINES AS TOPIC;

EID: 77950865888     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2009.12.014     Document Type: Review

References (89)

1. Leading Causes of Death and Hospitalizations in Canada - Public Health Agency of Canada http://www.phac-aspc.gc.ca.
2. Schull M.J., Morrison L.J., Vermeulen M., Redelmeier D.A. Emergency department overcrowding and ambulance transport delays for patients with chest pain. CMAJ 2003, 168:277-283.
3. Schull M.J., Vermeulen M., Slaughter G., Morrison L., Daly P. Emergency department crowding and thrombosis delays in acute myocardial infarction. Ann. Emerg. Med. 2004, 44:577-585.
4. Christenson J., Innes G., McKnight D., et al. Safety and efficiency of emergency department assessment of chest pain discomfort. CMAJ 2004, 170:1803-1807.
5. Li G., Lau J.T., McCarthy M.L., et al. Emergency department utilization in the United States and Ontario, Canada. Acad. Emerg. Med. 2007, 14:582-584.
6. Nawar E.W., Niska R.W., Xu J. National Hospital Ambulatory Medical Care Survey: 2005 emergency department summary. Adv. Data 2007, 386:1-32.
7. Alpert J.S., Thygesen K., Antman E., Bassand J.P. Myocardial infarction redefined-a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction. J. Am. Coll. Cardiol. 2000, 36:959-969.
8. Luepker R.V., Apple F.S., Christenson R.H., et al. AHA scientific statement. Case definitions for acute coronary heart disease in epidemiology and clinical research studies. Circulation 2003, 108:2543-2549.
9. Morrow D.A., Cannon C.P., Jesse R.L., et al. National Academy of Clinical Biochemistry laboratory medicine practice guidelines: clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Clin. Chem. 2007, 53:552-574.
10. Thygesen K., Alpert J.S., White H.D. Joint ESC/AACF/AHA/WHF task force for the redefinition of myocardial infarction. Universal definition of myocardial infarction. J. Am. Coll. Cardiol. 2007, 50:2173-2195.
11. Anderson J.L., Adams C.D., Antman E.M., et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: executive summary. Circulation 2007, 116:803-877.
12. Kleiman N.S., White H.D. The declining prevalence of ST elevation myocardial infarction in patients presenting with acute coronary syndromes. Heart 2005, 91:1121-1123.
13. Fox K.A., Steg P.G., Eagle K.A., et al. Decline in rates of death and heart failure in acute coronary syndromes, 1999-2006. JAMA 2007, 297:1892-1900.
14. Christenson R.H., Azzazy H.M. Cardiac point of care testing: a focused review of current National Academy of Clinical Biochemistry guidelines and measurement platforms. Clin. Biochem. 2009, 42:150-157.
15. Kavsak P.A., Zielinski N., Li D., McNamara P.J., Adeli K. Challenges of implementing Point-of-Care Testing (POCT) glucose meters in a pediatric acute care setting. Clin. Biochem. 2004, 37:811-817.
16. Khan A.I., Vasquez Y., Gray J., Wians F.H., Kroll M.H. The variability of results between point-of-care testing glucose meters and the central laboratory analyzer. Arch. Pathol. Lab. Med. 2006, 130:1527-1532.
17. Apple F.S. A new season for cardiac troponin assays: it's time to keep a scorecard. Clin. Chem. 2009, 55:1303-1306.
18. Report of the Joint International Society and Federation of Cardiology/World Health Organization task force on standardization of clinical nomenclature. Circulation 1979, 59:607-609. Nomenclature and criteria for diagnosis of ischemic heart disease.
19. Wu A.H.B., Wang X.-M., Gornet T.G., et al. Creatine kinase MB isoforms in patients with myocardial infarction and skeletal muscle injury. Ramifications for early detection of acute myocardial infarction. Clin. Chem. 1992, 38:2396-2400.
20. Hamilton R.W., Hopkins M.B., Shihabi Z.K. Myoglobinuria, hemoglobinuria, and acute renal failure [Clinical Conference]. Clin. Chem. 1989, 35:1713-1720.
21. Jaffe A.S., Landt Y., Parvin C.A., et al. Comparative sensitivity of cardiac troponin I and lactate dehydrogenase isoenzymes for diagnosis of acute myocardial infarction. Clin. Chem. 1996, 42:1770-1776.
22. Katus H.A., Remppis A., Looser S., Hallermayer K., Scheffold T., Kübler W. Enzyme linked immuno assay of cardiac troponin T for the diagnosis of acute myocardial infarction in patients. J. Mol. Cell. Cardiol. 1989, 21:1349-1353.
23. Bodor G.S., Survant L., Voss E., Smith S., Porterfield D., Apple F.S. Cardiac troponin T composition in normal and regenerating human skeletal muscle. Clin. Chem. 1997, 43:476-484.
24. Wu A.H.B., Apple F.S., Gibler W.B., et al. National Academy of Clinical Biochemistry Standards of Laboratory Practice: recommendations for the use of cardiac markers in coronary artery diseases. Clin. Chem. 1999, 45:1104-1121.
25. Apple F.S., Wu A.H.B., Jaffe A.S. European Society of Cardiology and American College of Cardiology guidelines for redefinition of myocardial infarction: how to use existing assays clinically and for clinical trials. Am. Heart J. 2002, 144:981-986.
26. Panteghini M., Pagani F., Yeo K.J., et al. Evaluation of imprecision for cardiac troponin assays at low-range concentrations. Clin. Chem. 2004, 50:327-332.
27. th percentile cutoff independent of assay imprecision (CV) for cTn monitoring for ruling out myocardial infarction. Clin. Chem. 2005, 51:2198-2200.
28. th percentile reference limits for cTn and creatine kinase MB mass for use with European Society of Cardiology/American College of Cardiology Consensus Recommendations. Clin. Chem. 2003, 49:1331-1336.
29. L. Babuin, A.S. Jaffe, Troponin: the biomarker of choice for the detection of cardiac injury. CMAJ;173:1191-1202.
30. Jaffe A.S. Chasing troponin: how low can you go if you can see the rise?. J. Am. Coll. Cardiol. 2006, 48:1763-1764.
31. Zethelius B., Johnston N., Venge P. Troponin I as a predictor of coronary heart disease and mortality in 70-year-old men: a community-based cohort study. Circulation 2006, 113:1071-1078.
32. Wallace T.W., Abdullah S.M., Drazner M.H., et al. Prevalence and determinants of troponin T elevation in the general population. Circulation 2006, 113:1958-1965.
33. Omland T., de Lemos J.A., Sabatine M.S., et al. A sensitive cardiac troponin T assay in stable coronary artery disease. N. Engl. J. Med. 2009, 361:2538-2547.
34. Apple F.S., Murakami M.M., Pearce L.A., Herzog C.A. Predictive value of cardiac troponin I and T for subsequent death in end-stage renal disease. Circulation 2002, 106:2941-2945.
35. th percentile for clinical decision-making. Clin. Chem. 2009, 55:85-92.
36. Babuin L., Vasile V.C., Rio Perez J.A., et al. Elevated cardiac troponin is an independent risk factor for short-and long-term mortality in medical intensive care unit patients. Crit. Care Med. 2008, 36:759-765.
37. Agewall S., Olsson T., Lowbeer C. Usefulness of troponin levels below the diagnostic cut-off level for acute myocardial infarction in predicting prognosis in unselected patients admitted to the coronary care unit. Am. J. Cardiol. 2007, 99:1257-1259.
38. Kavsak P.A., Newman A.M., Lustig V., et al. Long-term health outcomes associated with detectable Troponin I concentrations. Clin. Chem. 2007, 53:220-227.
39. Kavsak P.A., MacRae A.R., Lustig V., et al. The impact of the ESC/ACC redefinition of myocardial infarction and new sensitive troponin assays on the frequency of acute myocardial infarction. Am. Heart J. 2006, 152:118-125.
40. Apple F.S., Pearce L.A., Smith S.W., Kaczmarek J.M., Murakami M.M. Role of monitoring changes in sensitive cardiac troponin I assay results for early diagnosis of myocardial infarction and prediction of risk of adverse events. Clin. Chem. 2009, 55:930-937.
41. Kavsak P.A., Wang X., Ko D., MacRae A.R., Jaffe A.S. The value of serial measurements of troponin in patients with acute syndromes. Clin. Chem. Lab. Med. 2009, 47:M-A061. [abstract].
42. Roberts M.A., Hare D.L., Macmillan N., Ratnaike S., Sikaris K., Ierino F.L. Serial increased cardiac troponin T predicts mortality in asymptomatic patients treated with chronic haemodialysis. Ann. Clin. Biochem. 2009, 46:291-295.
43. Miller W.L., Hartman K.A., Burritt M.F., Grill D.E., Jaffe A.S. Profiles of serial changes in cardiac troponin T concentrations and outcome in ambulatory patients with chronic heart failure. J. Am. Coll. Cardiol. 2009, 54:1715-1721.
44. Kavsak P.A. Serial cardiac troponin T measurements in haemodialysis patients: absolute versus changing concentrations?. Ann Clin Biochem 2010, 47:97.
45. Melanson S.E., Morrow D.A., Jarolim P. Earlier detection of myocardial injury in a preliminary evaluation using a new troponin I assay with improved sensitivity. Am. J. Clin. Pathol. 2007, 128:282-286.
46. MacRae A.R., Kavsak P.A., Lustig V., et al. Assessing the requirement for the 6-hour interval between specimens in the American Heart Association classification of myocardial infarction in epidemiology and clinical research studies. Clin. Chem. 2006, 52:812-818.
47. Reichlin T., Hochholzer W., Bassetti S., et al. Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. N. Engl. J. Med. 2009, 361:858-867.
48. Keller T., Zeller T., Peetz D., et al. Sensitive troponin I assay in early diagnosis of acute myocardial infarction. N. Engl. J. Med. 2009, 361:868-877.
49. Wu A.H., Smith A., Schultz K., Lu A., Todd J., Wians F. Short- and long-term biological variation for cardiac troponin I using a high sensitivity assay: implications for clinical practice. Clin. Chem. 2009, 55:52-58.
50. Wu A.H., Fukushima N., Puskas R., Todd J., Goix P. Development and preliminary clinical validation of a high sensitivity assay for cardiac troponin using a capillary flow (single molecule) fluorescence detector. Clin. Chem. 2006, 52:2157-2159.
51. Latini R., Masson S., Anand I.S., Missov E., Carlson M., Vago T., et al. Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure. Circulation 2007, 116:1242-1249.
52. Kurz K., Giannitsis E., Zehelein J., Katus H.A. Highly sensitive cardiac troponin T values remain constant after brief exercise- or pharmacologic-induced reversible myocardial ischemia. Clin. Chem. 2008, 54:1234-1238.
53. Kavsak P.A., MacRae A.R., Yerna M.J., Jaffe A.S. Analytical and clinical utility of a next generation, highly sensitive cardiac troponin I assay for early detection of myocardial injury. Clin. Chem. 2009, 55:573-577.
54. Sabatine M.S., Morrow D.A., de Lemos J.A., Jarolim P., Braunwald E. Detection of acute changes in circulation troponin in the setting of transient stress test-induced myocardial ischaemia using an ultrasensitive assay: results from TIMI 35. E. Heart J. 2009, 30:162-169.
55. Wilson S.R., Sabatine M.S., Braunwald E., Sloan S., Murphy S.A., Morrow D.A. Detection of myocardial injury in patients with unstable angina using a novel nanoparticle cardiac troponin I assay: observations from the PROTECT-TIMI 30 trial. Am. Heart J. 2009, 158:386-391.
56. Venge P., Johnston N., Lindahl B., James S. Normal plasma levels of cardiac troponin I measured by the high-sensitivity cardiac troponin I access prototype assay and the impact on the diagnosis of myocardial ischemia. J. Am. Coll. Cardiol. 2009, 54:1165-1172.
57. Kavsak P.A., Wang X., Ko D.T., MacRae A.R., Jaffe A.S. Short- and long-term risk stratification using a next-generation, high-sensitivity research cardiac troponin (hs-cTnI) assay in an emergency department chest pain population. Clin. Chem. 2009, 55:1809-1815.
58. Kavsak PA, Ko DT, Wang X, MacRae AR, Jaffe AS. The 2007 Universal MI definition change criteria for risk stratification and high-sensitivity cardiac troponin I assays. Clin Chem in press.
59. Apple F.S., Wu A.H., Mair J., et al. Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. Clin. Chem. 2005, 51:810-824.
60. Jaffe A.S., Babuin L., Apple F.S. Biomarkers in acute cardiac disease: the present and the future. J. Am. Coll. Cardiol. 2006, 48:1-11.
61. Jaffe A.S. Cardiovascular biomarkers: the state of the art in 2006. Clin. Chim. Acta 2007, 381:9-13.
62. Blake G.J., Ridker P.M. C-reactive protein and other inflammatory risk markers in acute coronary syndromes. J. Am. Coll. Cardiol. 2003, 41:37S-42S.
63. Morrow D.A., Sabatine M.S., Brennan M.L., et al. Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18. Eur. Heart J. 2008, 29:1096-1102.
64. Maier W., Altwegg L.A., Corti R., et al. Inflammatory markers at the site of ruptured plaque in acute myocardial infarction: locally increased interleukin-6 and serum amyloid A but decreased C-reactive protein. Circulation 2005, 111:1355-1361.
65. Deliargyris E.N., Raymond R.J., Theoharides T.C., Boucher W.S., Tate D.A., Dehmer G.J. Sites of interleukin-6 release in patients with acute coronary syndrome and in patients with congestive heart failure. Am. J. Cardiol. 2000, 86:913-918.
66. Bonaca M.P., Morrow D.A. Defining a role for novel biomarkers in acute coronary syndromes. Clin. Chem. 2008, 54:1424-1431.
67. Eggers K.M., Lagerqvist B., Venge P., Wallentin L., Lindahl B. Prognostic value of biomarkers during and after non-ST-segment elevation acute coronary syndrome. J. Am. Coll. Cardiol. 2009, 54:357-364.
68. Sabatine M.S., Morrow D.A., de Lemos J.A., et al. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, c-reactive protein, and B-type natriuretic peptide. Circulation 2002, 105:1760-1763.
69. Mockel M., Danne O., Muller R., et al. Development of an optimized multimarker strategy for early risk assessment of patients with acute coronary syndromes. Clin. Chim. Acta 2008, 393:103-109.
70. Kavsak P.A., Ko D.T., Newman A.M., et al. Upstream markers provide for early identification of patients at high risk for myocardial necrosis and adverse outcomes. Clin. Chim. Acta 2008, 387:133-138.
71. Apple F.S., Smith S.W., Pearce L.A., Murakami M.M. Assessment of the multiple-biomarker approach for diagnosis of myocardial infarction in patients presenting with symptoms suggestive of acute coronary syndrome. Clin. Chem. 2009, 55:93-100.
72. Fesmire F.M., Christenson R.H., Fody E.P., Feintuch T.A. Delta creatine kinase-MB outperforms myoglobin at two hours during the emergency department identification and exclusion of troponin positive non-ST-Segment elevation acute coronary syndromes. Ann. Emerg. Med. 2004, 44:12-19.
73. Penttila K., Koukkunen H., Halinen M., et al. Myogloblin, creatine kinase MB isoforms and creatine kinase MB mass in early diagnosis of myocardial infarction in patients with acute chest pain. Clin. Biochem. 2002, 35:647-653.
74. Newby L.K., Storrow A.B., Gibler B., et al. Bedside multimarker testing for risk stratification in chest pain units: the chest pain evaluation by creatine kinase-MB, myoglobin, and troponin I (CHECKMATE) study. Circulation 2001, 103:1832-1837.
75. Sallach S.M., Nowak R., Hudson M.P., et al. A change in serum myoglobin to detect acute myocardial infarction in patients with normal troponin I levels. Am. J. Cardiol. 2004, 94:864-867.
76. Eggers K.M., Oldgren J., Nordenskjold A., Lindahl B. Diagnostic value of serial measurements of cardiac markers in patients with chest pain: Limited value of adding myoglobin to troponin I for exclusion of myocardial infarction. Am. Heart J. 2004, 148:574-581.
77. Ilva T., Eriksson S., Lund J., et al. Improved early risk stratification and diagnosis of myocardial infarction, using a novel troponin I assay concept. Eur. J. Clin. Invest. 2005, 35:112-116.
78. Kavsak P.A., MacRae A.R., Newman A.M., et al. Effects of contemporary troponin assay sensitivity on the utility of the early markers myoglobin and CKMB isoforms in evaluating patients with possible acute myocardial infarction. Clin. Chim. Acta 2007, 380:213-216.
79. Wollert K.C., Kempf T., Peter T., et al. Prognostic value of growth-differentiation factor-15 in patients with non-ST elevation acute coronary syndrome. Circulation 2007, 115:962-971.
80. Kilcullen N., Viswanathan K., Das R., et al. Heart-type fatty acid-binding protein predicts long-term mortality after acute coronary syndrome and indentifies high-risk patients across the range of troponin values. J. Am. Coll. Cardiol. 2007, 50:2061-2067.
81. Heeschen C., Dimmeler S., Hamm C.W., et al. Pregnancy-associated plasma protein-A levels in patients with acute coronary syndromes: comparison with markers of systemic inflammation, platelet activation, and myocardial necrosis. J. Am. Coll. Cardiol. 2005, 45:229-237.
82. Qin Q.P., Wittfooth S., Pettersson K. Measurement and clinical significance of circulating PAPP-A in ACS patients. Clin. Chim. Acta 2007, 380:59-67.
83. Miedema M.D., Conover C.A., MacDonald H., et al. Pregnancy-associated plasma protein-a elevation in patients with acute coronary syndrome and subsequent atorvastatin therapy. Am. J. Cardiol. 2008, 101:35-39.
84. Tertti R., Wittfooth S., Porela P., Airaksinen K.E., Metsarinne K., Pettersson K. Intravenous administration of low molecular weight and unfractionated heparin elicits a rapid increase in serum pregnancy-associated plasma protein A. Clin. Chem. 2009, 55:1214-1217.
85. Kavsak P.A., Wang X., Henderson M., Ko D.T., MacRae A.R., Jaffe A.S. PAPP-A as a marker of increased long-term risk in patients with chest pain. Clin. Biochem. 2009, 42:1012-1018.
86. Kavsak P.A., Henderson M., Ko D.T., Wang X., MacRae A.R., Jaffe A.S. Another potential marker linking gender and cardiac mortality: PAPP-A-a new marker in risk stratification for women presenting with chest pain. Clin. Chim. Acta 2009, 408:139-140.
87. Eggers K.M., Dellborg M., Johnston N., et al. Myeloperoxidase is not useful for the early assessment of patients with chest pain. Clin. Biochem. 2009 Oct 12, [electronic publication ahead of print].
88. Wu A.H., Jaffe A.S. The clinical need for high-sensitivity cardiac troponin assays for acute coronary syndromes and the role for serial testing. Am. Heart J. 2008, 155:208-214.
89. Jaffe A.S., Katus H. Acute coronary syndrome biomarkers: the need for more adequate reporting. Circulation 2004, 110:104-106.